The lack of association between monoamine oxidase (MAO) intron 13 polymorphism and platelet MAO-B activity among men by Pivac, Nela et al.
  
 
 
 
    
 
Središnja medicinska knjižnica 
 
 
 
 
 
 
 
 
 
Pivac, N., Knežević, J., Mustapić, M., Deželjin, M., Muck-Šeler , D., Kozarić-Kovačić, 
D., Balija, M., Matijević, T., Pavelić, J. (2006) The lack of association between 
monoamine oxidase (MAO) intron 13 polymorphism and platelet MAO-B activity 
among men. Life sciences, 79 (1). pp. 45-49. 
 
 
http://www.sciencedirect.com/science/journal/00243205 
 
http://medlib.mef.hr/129/ 
 
 
 
 
 
 
 
 
 
University of Zagreb Medical School Repository 
http://medlib.mef.hr/ 
 
 
 1 
The lack of association between monoamine oxidase (MAO) intron 13 
polymorphism and platelet MAO-B activity among men 
 
MAO-B genotypes and activity in men 
 
 
Nela Pivaca*, Jelena Knezevica, Maja Mustapica, Martina Dezeljina, Dorotea 
Muck-Selera, Dragica Kozaric-Kovacicb, Melita Balijac, Tanja Matijevica, 
Jasminka Pavelica  
 
 
aDivision of Molecular Medicine, Rudjer Boskovic Institute, Zagreb, Croatia, and  
bDepartment of Psychiatry, Referral Centre for the Stress related Disorders of the 
Ministry of Health of the Republic of Croatia, University Hospital Dubrava, 
Zagreb, Croatia, and cCroatian Institute for Transfusion Medicine, Zagreb, Croatia 
Corresponding author: Division of Molecular Medicine, Rudjer Boskovic 
Institute, POBox 180, HR-10002 Zagreb, Croatia, Phone: 385 1 4571 207; Fax: 
385 1 456 1010; e-mail: npivac@irb.hr 
  
 
 2 
Abstract: Monoamine oxidase (MAO), a mitochondrial flavine containing 
enzyme, exists in two isoenzymes, MAO-A and MAO-B. Platelets contain MAO-
B subtype, proposed to be a biomarker for different personality characteristics and 
vulnerability for substance abuse. The most common polymorphism of MAO-B 
gene, a single base change (A or G) occurs in intron 13. It has been proposed to be 
a functional polymorphism, controlling the activity of MAO-B in platelets. The 
aim of the study was to determine the association between platelet MAO-B 
activity and MAO-B intron 13 polymorphism in 225 racially and ethnically 
uniform healthy Caucasian men of the Croatian origin. Our results showed that 
platelet MAO-B activity did not differ between subjects subdivided into those 
with «A allele» or «G allele». This polymorphism of the MAO-B gene did not 
control the activity of the MAO-B in platelets. Platelet MAO-B activity was 
associated only with the smoking status, and it was significantly decreased in 
smokers when compared to nonsmokers. No significant association was found 
between MAO-B polymorphism and smoking status. In healthy individuals of the 
Croatian origin, the studied MAO-B polymorphism showed a lack of functional 
importance in regulating MAO-B activity in platelets. Since different populations 
may vary in the association between functional polymorphism and the MAO-B 
activity, and the genotype of transcription factor AP-2β was reported to be 
associated with altered platelet MAO-B activity, and with specific personality 
traits, further studies on different populations should be conducted to elucidate the 
molecular mechanism/s regulating platelet MAO-B activity. 
 
Keywords: Monoamine oxidase (MAO), platelets, MAO-B activity, MAO-B 
intron 13 polymorphism, Control male subjects  
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Introduction 
 
Monoamine oxidase (MAO) is a mitochondrial flavine containing enzyme. There 
are two types of MAO: MAO-A and MAO-B. Both catalyze the deamination of 
different neurotransmitter and xenobiotic amines in the central nervous system 
and in the periphery. Platelets contain only MAO-B, which shares the identical 
amino acid sequence with MAO-B in central nervous system (Billett, 2004; 
Oreland, 2004). The main substrates for MAO-B are exogenous monoamines such 
as phenyletylamine and benzylamine, as well as dopamine and tyramine. Two 
forms of MAO isoezymes differ in their substrate and inhibitor specificity and are 
encoded by the separate genes. Both genes are located side-by-side on the 
chromosome X (Xp11.23-11.4), have 15 exons and have identical exon-intron 
organization. MAO-B gene is 60 Kb long. The corresponding protein has 520 
amino acids. Both MAO isoforms share a 70% amino acid sequence homology.  
 
Platelet MAO or MAO-B has been proposed to be a biomarker for different 
personality disorders, including aggressive behavior, sensation seeking behavior, 
monotony avoidance, and vulnerability to psychiatric disorders and substance 
abuse (Schalling et al., 1987; Garpenstrand et al., 2000; Oreland, 2004). MAO-B 
activity in platelets has been reported to be affected by various factors, such as 
sex, age, ethnicity, and smoking (Garpenstrand et al., 2000; Oreland et al., 2002; 
Fowler et al., 2003; Oreland, 2004; Costa-Mallen et al., 2005a).  
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The most common polymorphism of MAO-B gene occurs in polymorphic repeat 
region of the intron 13, and includes a single base change (A or G), (Girmen et al., 
1992). The association between MAO-B genotype and MAO-B activity in 
platelets has been proposed, linking lower enzyme activity with «A-allele» in 
blood (Garpenstrand et al., 2000). However, the opposite results have been 
reported, showing no association between MAO-B genotype and MAO-B activity 
in platelets (Girman et al., 1992), or lower enzyme activity in subjects with «G-
allele» in postmortem human brains (Balciuniene et al., 2002). Since smoking 
decreases platelet MAO-B activity (Fowler et al., 2003), we divided our subjects 
according to the smoking status. To elucidate the association between platelet 
MAO-B activity and MAO-B genotype (i.e. G/A substitution on intron 13), and to 
avoid the influence of sex and ethnicity on platelet MAO activity and on the 
frequency of MAO-B alleles (Costa-Mallen et al., 2005a), we determined 
simultaneously platelet MAO-B activity and MAO-B genotype in a large group of 
racially and ethnically uniform healthy Caucasian men from Croatia.  
 
Materials and methods 
 
Subjects 
The study included randomly selected 225 male Caucasian healthy subjects of the 
Croatian origin, 41.97 ± 12.36 years old (range 20-65 years). Participants were 
healthy blood donors (Transfusion Clinic, Zagreb, Croatia), with no personal or 
family history of psychopathology, free of neurodegenerative or psychiatric 
disorders, and no medical treatment. All participants fulfilled the questionnaire 
answering the questions about their medical history, drinking and smoking habits. 
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All participants agreed to give a blood sample, to participate in the study, and gave 
their written informed consent. The study was approved by the Ethic committee. 
 
Biochemical analysis 
 
Blood (4 ml) was drawn from cubical vein at 8.00 a.m. in a plastic syringe with 1 
ml of acid citrate dextrose (ACD) anticoagulant. Platelet-rich-plasma (PRP) was 
obtained by centrifugation (935 x g) for 70 s at room temperature. Platelets were 
sedimented by further centrifugation of PRP at 10,000 x g for 5 min. The platelet 
pellet was washed with saline and centrifuged again. Platelets were destroyed by 
sonication (20 kHz, amplitude 8 x 10-3 mm for 30 sec). Platelet MAO-B activity 
was determined by the spectrofluorimetric method, using kynuramine as a 
substrate, by a slight modification of the method of Krajl (1965), as previously 
described (Pivac et al., 2002). Briefly, specimens of standard, blank (water) and 
platelet sonicates (100 µl) were analyzed in duplicates in phosphate buffer (0.5 M, 
pH 7.4), incubated 60 min on 37° C with kynuramine. The reaction was stopped 
by adding ice-cold 1N NaOH. The measurement of 4-hydroxyquinoline (4-HOQ) 
fluorescence, a product of kynuramine, was performed on a Varian Cary Eclipse 
spectrofluorimeter, with an exciting wavelength of 310 nm and emitted 
wavelength of 380 nm. Platelet protein was determined by the method of Lowry et 
al.  (1951). 
 
The DNA analysis 
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Genotyping methods were performed in our laboratories in Division of Molecular 
Medicine at the Rudjer Boskovic Institute. DNA was isolated from blood by a 
standard salting out method. DNA samples were genotyped for the MAO-B intron 
13 G/A polymorphism in ABI Prism 7000 Sequencing Detection System 
apparatus (ABI, Foster City, USA) using Taqman-based allele-specific 
polymerase chain reaction assay, according to the procedure described by the 
Applied Biosystems. The primers and probes were purchased from Applied 
Biosystems (ABI, Foster City, USA).  
 
Statistical methods 
 
All data (expressed as mean ± standard deviations) were evaluated by one-way 
analysis of variance (ANOVA), followed by Tukey’s multiple comparison test. 
Two-way ANOVA was used to test the significance of the several variables: 
smoking, genotype, and age, on platelet MAO activity, and to test the interactions 
between them. The correlation between parameters was determined by Pearson’s 
correlation coefficient. The frequency of smokers and nonsmokers in subjects 
with particular genotypes (A or G) was determined by a χ2 test. Hardy Weinberg 
equilibrium was tested with a χ2 test. The significance was accepted when P<0.05. 
 
Results 
 
The subjects were divided according to the smoking status into 161 nonsmokers 
and 64 smokers. Platelet MAO-B activity (nmol 4OHQ/mg protein/h) differed 
significantly [F(1,223)= 12.462, P<0.001, one way ANOVA] between smokers 
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(12.54 ± 6.52) and nonsmokers (15.53 ± 5.40), with significantly (P<0.05, 
Tukey’s test) lower platelet MAO-B activity in smokers than in nonsmokers. 
Platelet MAO-B activity was reduced by 19.3% in smokers when compared to 
nonsmokers.  
 
To evaluate the influence of the MAO-B intron 13 polymorphism on platelet 
MAO-B activity, we divided subjects according to those with “A-allele” or “G-
allele”. One-way ANOVA showed no significant [F(1,223)=0.421, P=0.517, one-
way ANOVA] difference in platelet MAO-B activity (nmol 4OHQ/mg protein/h) 
between 124 subjects with “A-allele” (14.91 ± 6.09) and 101 subjects with “G-
allele” (14.40 ± 5.65). The MAO-B polymorphism was in the Hardy Weinberg 
equilibrium (χ2 = 0.985, df = 1; P=0.321).  
 
Fig. 1 shows that smoking status significantly [F(3,223)= 4.409, P=0.005, one-
way ANOVA] affected platelet MAO-B activity in smokers and nonsmokers 
subdivided according to the “A-allele” or “G-allele” (Fig. 1). Smokers with “A-
allele” or “G-allele” had significantly (P<0.05, Tukey’s test) lower platelet MAO-
B activity than nonsmokers with “A-allele” or “G-allele”. Platelet MAO-B 
activity did not differ significantly (P>0.05, Tukey’s test) within smokers with 
“A-allele” or “G-allele”, or within nonsmokers with “A-allele” or “G allele” (Fig. 
1). The frequency of the occurrence of smokers and nonsmokers was not 
significantly different (χ2 = 0.0058, df = 1; P=0.939, Odds Ratio= 1.166, 95% CI 
= 0.06493- 2.092) in subjects with “A-allele” or “G-allele”.  
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To further evaluate the effect of MAO-B polymorphism (“A-allele” or “G-allele”) 
and smoking status (smoking or nonsmoking) on platelet MAO-B activity, and to 
test the interaction between these variables, two-way ANOVA was used. It 
revealed a significant main effect [F(2,221)=3.168, P=0.044], significant effect of 
smoking [F(1,221)=5.894, P=0.016], but no significant effect of MAO-B 
polymorphism [F(1,221)=0.338, P=0.567], and no significant interaction between 
smoking and MAO-B polymorphism [F(1,221)=0.830, P=0.373] on platelet 
MAO-B activity. When age was tested as a covariate, two way ANOVA showed 
that age of the subjects did not affect significantly [F(1,220)=1.751, P=0.187] 
platelet MAO-B activity.  
 
To determine whether platelet MAO-B activity correlates with age of the subjects, 
or with the number of cigarettes smoked per day, Pearson’s correlation coefficient 
was used. There was no significant correlation between platelet MAO-B activity 
and age of the subjects in 64 smokers (r=0.058; P=0.649) or 161 nonsmokers (r=-
0.05; P=0.529). No significant correlation was found when smokers were 
subdivided into 37 subjects with “A-allele” (r=-0.022; P=0.987) or 27 subjects 
with “G-allele” (r=0.168; P=0.402), or when nonsmokers were subdivided into 87 
subjects with “A-allele” (r=0.001; P=0.990) or 74 subjects with “G-allele” (r=-
0.118; P=0.318), respectively.  
 
Number of smoked cigarettes per day was not significantly correlated with platelet 
MAO-B activity in 37 smokers with “A-allele” (r=-0.224; P=0.145) or 27 subjects 
with “G-allele” (r=-0.013; P=0.951).  
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Discussion 
 
In a well characterized, large group of ethnically and racially uniform, Caucasian 
healthy male subjects of the Croatian origin, free of neurodegenerative or 
psychiatric disorders, and without medical treatment, platelet MAO-B activity did 
not differ between subjects subdivided according to the polymorphism in intron 
13 of the MAO-B gene, into subjects with «A allele» or «G allele». Although the 
association between MAO-B genotype and MAO-B activity in platelets has been 
proposed (Garpenstrand et al., 2000; Balciuniene et al., 2002), but also disputed 
(Girman et al., 1992), our results showed comparable values of platelet MAO-B 
activity in subjects carrying «A allele» or «G allele». These data indicate that this 
polymorphism of MAO-B gene does not control the activity of the MAO-B in 
platelets. In contrast to our data, it has been reported that subjects carrying «A 
allele» have lower platelet MAO-B activity (Garpenstrand et al., 2000), and the 
authors proposed that MAO-B polymorphism represents a functional 
polymorphism associated with altered platelet MAO-B activity. The discrepancies 
between studies might be explained with the slightly different method used to 
identify the polymorphism in intron 13 (A/G) of the human gene encoding MAO-
B, by the different populations used (Balciuniene et al., 2002), and the fact that 
our study, as opposed to study of Garpenstrand et al. (2000) with 55 male 
nonsmokers, included much larger groups (i.e. 161 nonsmokers and 64 smokers). 
Our results are in line with the lack of any correlation between MAO-B 
polymorphism and platelet MAO-B activity in 70 healthy male nonsmokers (Filic 
et al., 2005), obtained on the same population, although this group used slightly 
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different methods for the determination of platelet MAO-B activity and MAO-B 
polymorphism.  
 
As expected, platelet MAO-B activity was considerably associated with the 
smoking status, and it was significantly increased in male nonsmokers when 
compared to male smokers. Smoking is a factor contributing to a lower MAO-B 
activity (Fowler et al., 2003; Pivac et al., 2005), and decreased binding of 3H-
lazabemide to MAO-B in the right amygdaloidal complex has been found in 
postmortem brains of the smoking subjects (Karolewitz et al., 2005). It is assumed 
that factors in the cigarette smoke might be associated with development of 
addiction (Fowler et al., 2003). Smoking is one of the most important problems in 
public health, a major risk for mental health, and patients with different 
psychiatric disorders are often heavy smokers. The possible neurobiological basis 
of smoking, i.e. the effect of nicotine from the tobacco smoke, involves the release 
of the brain dopamine, noradrenalin or serotonin, and the inhibition of the activity 
of MAO-A and MAO-B (Fowler et al., 2003), linking smoking with other forms 
of addictions, and/or psychiatric disorders (Berlin et al., 1995). In line with a 
proposed inhibitory effect of smoking on platelet MAO-B activity (Berlin et al., 
1995; Oreland et al., 2002; Oreland, 2004; Pivac et al., 2005), we have found a 
significant decreasing effect of tobacco smoke on platelet MAO-B activity in 
healthy male subjects.  
  
Although the dopaminergic pathways play a significant role in addiction (such as 
tobacco consumption) and award, and therefore it might be expected that MAO-B 
polymorphism is important for the control of smokin
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significant differences in platelet MAO-B activity between smokers with “A-
allele” or “G-allele”, or between nonsmokers with “A-allele” or “G-allele”, and no 
significant interaction between smoking and MAO-B polymorphism. In addition, 
the frequency of the occurrence of tobacco consumption did not differ in subjects 
with “A-allele” or “G-allele”. No significant association was found between 
MAO-B intron 13 polymorphism and smoking status in control men or women 
(Costa-Mallen et al., 2005a). Our data are in line with the lack of significant effect 
of the genetic variants in dopamine metabolic enzymes (MAO-A and MAO-B and 
dopamine-β-hydroxylase) on the tobacco consumption in the large sample 
(Johnstone et al., 2002). Since the genetic predisposition to smoking is determined 
by multiple genes, recently the particular combination of the genotypes for MAO-
B and dopamine D2 receptor genes was found to be associated with a higher risk 
for smoking behavior in men (Costa-Mallen et al., 2005a). 
 
In our study platelet MAO-B activity was not correlated with the number of 
cigarettes smoked per day, a finding in line with no relationship between the 
metabolite of nicotine in plasma, cotinine concentration, and platelet MAO-B 
activity (Fowler et al., 2003). Other factors from the cigarette smoke, norharman 
and harman, two substances belonging to the β-carboline alkaloid family, have 
been shown to reversibly inhibit human MAO-A and MAO-B activities (Herraiz 
and Chaparro, 2005). Since β-carboline alkaloids are pharmacologically active 
compounds affecting serotonergic, benzodiazepine, opioid and imidazoline 
receptors, and might exert antidepressant-like effects, this might explain some 
“neuroprotective” effects of smoking, e.g. lower incidence of Parkinson’s disease 
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in smokers who have decreased platelet MAO-B activity (Herraiz and Chaparro, 
2005).  
 
Platelet MAO-B activity is under influence of sex, and sex differences are found in 
platelet MAO-B activity, with higher values of platelet MAO-B in female than in 
male subjects (Muck-Seler et al., 1991; Verkes et al., 1998; Snell et al., 2002; 
Oreland, 2004; Coccini et al., 2005; Pivac et al., 2005). To avoid the influence of 
sex and ethnicity on platelet MAO-B activity and on the frequency of MAO-B 
alleles (Costa-Mallen et al., 2005a), present study included only male control 
subjects. The inclusion criteria of only healthy men, who fulfilled the 
questionnaires about their medical status, excluded the possible influence of the 
different disorders such as pernicious anemia, Alzheimer's disease, Parkinson's 
disease and Huntington’s chorea (Oreland, 2004), that have been shown to 
increase platelet MAO-B activity. Although older age has been associated with 
increased values of MAO-B in platelets (Nicotra et al., 2004), and in brain 
(Fowler et al., 2003; Karolewitz et al., 2005), but also the lack of significant effect 
of age on platelet MAO-B activity has been observed (Coccini et al., 2005), we 
did not find any significant correlation between platelet MAO-B activity and age 
of the subjects either in smokers or in nonsmokers. In addition, age as a covariate 
did not affect significantly platelet MAO-B activity in the large groups of control 
male subjects in our study, presumably because our 225 healthy male blood 
donors were 42 years old (the dispersion of the age data was less than 2%), and 
slight nonsignificant age-related increase of platelet MAO-B activity was detected 
only in the older male subjects than the group used in our study (Coccini et al., 
2005).  
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Platelet MAO-B activity is reported to be associated with personality traits such as 
impulsiveness, extroversion, sensation seeking, neuroticism, or novelty seeking 
(Kozaric-Kovacic et al., 2000; Oreland et al., 2002; Oreland, 2004), impulse and 
affect dysregulation (Verkes et al., 1998), and might represent a biological marker 
for the personality traits that increase the vulnerability for drug-abuse, social mal-
adaptation or dysinhibitory psychopathology (Oreland et al., 2002; Oreland, 2004; 
Longato-Stadler et al., 2002). The mechanism controlling the enzyme activity is 
still not clear, and our (present study) and other data (Johnstone et al., 2002) do 
not support the hypothesis that MAO-B polymorphism with a single base change 
(A or G) on the intron 13, is a functional one, i.e. that this single polymorphism 
regulates MAO-B activity. Our data are not in contradiction with the results 
obtained on the postmortem brain tissue, where “A-allele” was significantly 
associated with elevated MAO-B activity in the brain, when compared to 
individuals that have “G-allele” (Balciuniene et al., 2002). Namely, although 
MAO-B in blood and brain shares the identical amino acid sequence (Coccini et 
al., 2005), MAO-B is expressed in a cell- and tissue-specific manner (Billett, 2004 
Costa-Mallen et al., 2005b), no association was found in the activity of MAO-B in 
platelets and the brain (Winblad et al., 1979), and therefore, MAO-B might be 
regulated differently in the blood and brain (Ekblom et al., 1998). In addition, 
different populations may vary in the association between functional 
polymorphism and the enzyme activity (Balciuniene et al., 2002).   
 
In conclusion, our results have shown that MAO-B polymorphism (G/A 
substitution in intron 13) showed a lack of functional importance in regulating 
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MAO-B activity in platelets in a large group of ethnically and racially uniform, 
healthy Causation male subjects of the Croatian origin. Since the genotype of 
transcription factor AP-2β was reported to be associated with altered platelet 
MAO-B activity (Damberg et al., 2000a), and with specific personality traits 
(Damberg et al., 2000b), further studies on different populations (Balciuniene et 
al., 2002), with large groups of subjects, should be conducted to elucidate the 
molecular mechanism/s regulating platelet MAO-B activity. 
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Fig 1. Platelet MAO-B activity (nmol 4OHQ/mg protein/h) in healthy male 
subjects of the Croatian origin, subdivided according to the smoking status 
(smokers and nonsmokers) and MAO-B polymorphism (subjects with “A-
allele” and subjects with “G-allele”). Numbers in the parenthesis are the 
number of subjects. Results are means ± standard deviations. *P<0.05 vs. the 
values in the corresponding nonsmokers (Tukey’s test). 
 
 
 
 
 
